While berberine supplements are now available, it is important to know more about it
October 2023: JAMA Research Letter Warns of Possible Ozempic Risks A research letter filed in the Journal of the American Medical Association alleges the risk of adverse gastrointestinal events associated with the use of GLP-1 agonists that are used not only to treat diabetes but also off-label for weight loss
Through the inhibition of gastric emptying and reduction of food intake, GLP-1 receptor agonists can significantly suppress nutrient absorption, potentially leading to a decrease in muscle mass [54, 60]
Because of the promising potential shown by IV hydration, health and wellness experts are working hard to realize the full potential of IV therapies
Antonia SJ, Lpez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al
So it might help if you have both diabetes and PCOS, and your doctor thinks its a good choice over other diabetes treatments